Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
9XEpgweK9GE5dNMj
